---
symbol: "MRNA"
name: "Moderna"
date: 2026-09-30
change_pct: -4.301952189204342
direction: "down"
event_type: "regulatory_legal"
url: "https://perplo.app/why/MRNA/2026-09-30"
updated_at: 2026-09-30T13:06:32.815Z
---

# Why Moderna (MRNA) fell 4.30% on September 30, 2026

Moderna (MRNA) fell 4.30% on September 30, 2026 — Patent loss in Bayer vaccine case hits biotech.

## What happened

A federal court refused to dismiss Bayer's patent infringement case against Pfizer, BioNTech, and Moderna over mRNA vaccine technology, allowing the lawsuit to proceed to trial.

## Why it moved

The denial of a motion to dismiss keeps material royalty and damages risk alive in Moderna's mRNA vaccine economics; the company now faces trial exposure that could require licensing payments or impose product…

## Why it matters

Within Healthcare & Biotech, the ruling underscores IP risk in the mRNA space — a foundational asset class for both Moderna and the sector; if Bayer wins, it creates a precedent and cost structure that could ripple…

## What would break the thesis

If the court later narrows Bayer's claims, finds non-infringement, or the parties settle on immaterial terms, the risk dissolves; also monitor trial timeline — a long litigation runway keeps uncertainty elevated and…

## Sources

- [Pfizer, BioNTech and Moderna lose bid to dismiss Bayer patent case](https://www.investing.com/news/stock-market-news/pfizer-biontech-and-moderna-lose-bid-to-dismiss-bayer-patent-case-93CH-4921035) — Investing.com
- [Citi tells investors it’s time to sell Moderna after 600%-plus stock gains](https://www.marketwatch.com/story/citi-tells-investors-its-time-to-sell-moderna-after-600-plus-stock-gains-84cb9b62?mod=mw_rss_topstories) — MarketWatch

---

Trade MRNA perpetual futures 24/7 onchain: https://perplo.app/asset/MRNA